Noticias y Actividades de Xenetic Biosciences
Ejecutivos
Ver el organigrama con sus 10 ejecutivos principales
Biografías más buscadas en Xenetic Biosciences
- James Parslow, Interim Chief Executive Officer
- Roger Kornberg, Director
- Adam Logal, Chairman of the Board
Crear su alerta
para seguir los movimientos de los ejecutivos en Xenetic Biosciences.
Biotecnología
Xenetic Biosciences tiene 2.351 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Genus (Reino Unido).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Xenetic Biosciences
- Press Releases :: Xenetic Biosciences, Inc. (XBIO)
- Xenetic Biosciences, Inc. Releases Virtual Investor
- Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma :: Xenetic Biosciences, Inc. (XBIO)
- Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results :: Xenetic Biosciences, Inc. (XBIO)
- Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses :: Xenetic Biosciences, Inc. (XBIO)
- Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting :: Xenetic Biosciences, Inc. (XBIO)
- Press Releases :: Xenetic Biosciences, Inc. (XBIO)
- Xenetic Biosciences, Inc. Releases Virtual Investor
- Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform :: Xenetic Biosciences, Inc. (XBIO)
- Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program :: Xenetic Biosciences, Inc. (XBIO)
- View more press releases Close
Redes sociales sobre Xenetic Biosciences
- Xenetic Biosciences en Wikipedia, Google News y Yahoo Finance
- Xenetic Biosciences en LinkedIn, Twitter y YouTube
